Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Lynparza On Track For Broad Frontline Use In Prostate Cancer

Leading PARP Inhibitor’s Uses Keep Expanding

Executive Summary

AstraZeneca and Merck & Co’s latest results put them far ahead of competitors in prostate cancer in reaching patient regardless of their mutational status.

You may also be interested in...



AstraZeneca/Merck Reinforce Lynparza’s Prostate Cancer Position With First-Line Data

The companies published data showing the drug was effective in patients with both homologous recombinant repair mutated and non-mutated disease.

SIFI Among EU Fast-Track Hopefuls With ‘World’s First’ Drug For Parasitic Eye Infection

SIFI is set to learn whether the European Medicines Agency will agree that its planned EU marketing application for Akantior merits an accelerated assessment, as is Janssen for its combination treatment for prostate cancer.

Quick Listen: Scrip's Five Must-Know Things

In this week's podcast edition of Five Must-Know Things: Lynparza poised for expansion in prostate cancer; zuranolone faces challenges in depression; Novartis transfers products and cuts jobs in India; US call to build Alzheimer’s infrastructure; and Indian legal row over COVID spray product.

Related Content

Topics

Related Companies

Latest News
UsernamePublicRestriction

Register

SC145896

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel